Clinical trials
Phase 2 Arthritis, Rheumatoid trials in Poland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
141 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2005 | 5 |
| 2006 | 6 |
| 2007 | 7 |
| 2008 | 12 |
| 2009 | 8 |
| 2010 | 11 |
| 2011 | 11 |
| 2012 | 12 |
| 2013 | 7 |
| 2014 | 4 |
| 2015 | 6 |
| 2016 | 12 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 7 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 8 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 106 |
| Terminated | 23 |
| Recruiting | 7 |
| Active, not recruiting | 5 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pfizer | 10 |
| Eli Lilly and Company | 9 |
| AbbVie | 7 |
| AstraZeneca | 7 |
| GlaxoSmithKline | 6 |
| Hoffmann-La Roche | 6 |
| Janssen Research & Development, LLC | 6 |
| Lakefront Biotherapeutics NV | 6 |
| Novo Nordisk A/S | 5 |
| Amgen | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Arthritis, Rheumatoid | 141 |
| Arthritis | 9 |
| Inflammation | 5 |
| Autoimmune Diseases | 4 |
| Joint Diseases | 4 |
| Musculoskeletal Diseases | 4 |
| Rheumatic Diseases | 3 |
| Arthritis, Psoriatic | 2 |
| Connective Tissue Diseases | 2 |
| Lupus Erythematosus, Systemic | 2 |
Trials
Showing 1 to 25 of 141. Each trial links to its page on Pharma Observatory.
41 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.